ArticleLipids in health and disease2026
TyHGB combined with diagonal earlobe crease and traditional risk factors for constructing a diagnostic model of coronary heart disease.
Article in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Waist circumference partially mediates the non-linear association between TyHGB and MASLD in non-diabetic Japanese adults.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTyHGB is a novel insulin resistance (IR)-related indicator, and its association with coronary heart disease (CHD) remains unclear. Additionally, studies have shown a close correlation between the diagonal earlobe crease (DELC) and CHD, yet it has not been fully applied in clinical practice to date. Therefore, this study constructed and validated a diagnostic model for CHD by combining TyHGB and DELC.
methodsA total of 1664 patients suspected of CHD who underwent coronary angiography (CAG) in the Department of Cardiology, Chengde Central Hospital from September 2021 to April 2025 were recruited for this study. Participants were categorized into a CHD group (n = 1,316) and a non-CHD group (n = 348). Univariate and multivariate logistic regression analyses were employed to assess the associations of TyHGB, DELC, and other relevant factors with CHD. Restricted cubic spline (RCS) analysis was employed to assess the dose-response correlation between TyHGB and the risk of CHD, and TyHGB levels were compared across quartiles. A nomogram incorporating TyHGB and DELC was developed, and its diagnostic performance was assessed using decision curve analysis (DCA) and receiver operating characteristic (ROC) curves.
resultsAge, sex, hypertension, diabetes, CR, Lp(a), TyHGB, and DELC were identified as independent risk factors for CHD through multivariate logistic regression analysis (P < 0.05). RCS curve analysis demonstrated a linear relationship between TyHGB and CHD risk (P for nonlinear = 0.477). Further quartile grouping of TyHGB revealed a progressive increase in CHD risk with rising TyHGB levels. Compared to the first quartile group, patients in the fourth quartile group exhibited a 2.087-fold higher risk of CHD (95% CI: 1.374–3.170). Optimal predictive variables were selected in the training set using Lasso regression and multivariate logistic regression. ROC curves were utilized to validate diagnostic performance, with the training set yielding an area under the curve (AUC) of 0.706 (95% CI: 0.669–0.743) and the validation set an AUC of 0.716 (95% CI: 0.657–0.775).
conclusionsBoth TyHGB and DELC have been identified as independent risk factors for CHD, with a linear relationship observed between TyHGB levels and CHD risk. A diagnostic model for CHD, developed by integrating TyHGB, DELC, and traditional risk factors, demonstrates strong diagnostic efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.